{"id":"placebo-for-telmisartan-80mg","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the baseline efficacy and safety profile of the active drug (Telmisartan 80mg) by comparison. Any observed effects are attributed to natural disease progression, patient expectation, or other non-pharmacological factors.","oneSentence":"Placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:32.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension)"}]},"trialDetails":[{"nctId":"NCT06647745","phase":"PHASE3","title":"A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension","status":"RECRUITING","sponsor":"THPharm Corp.","startDate":"2025-04-10","conditions":"Type 2 Diabetes, Hypertension","enrollment":221},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT04021550","phase":"EARLY_PHASE1","title":"Improving 24-hour Blood Pressure in Obstructive Sleep Apnea","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2023-05","conditions":"Obstructive Sleep Apnea","enrollment":""},{"nctId":"NCT00981526","phase":"PHASE4","title":"Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":66},{"nctId":"NCT01204398","phase":"PHASE3","title":"Telmisartan+Amlodipine Fixed Dose Combination in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11","conditions":"Hypertension","enrollment":27},{"nctId":"NCT00153062","phase":"PHASE4","title":"PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Stroke","enrollment":20332},{"nctId":"NCT02087540","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-05","conditions":"Hypertension, Hyperlipidemia","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo(for Telmisartan 80mg)","genericName":"Placebo(for Telmisartan 80mg)","companyName":"IlDong Pharmaceutical Co Ltd","companyId":"ildong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in Phase 3 clinical trial for Telmisartan 80mg (hypertension).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}